Eisai Co Ltd ESALF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ESALF is a good fit for your portfolio.
News
-
Merck, Eisai: Keytruda/Lenvima Combo Fails in 1st-Line Endometrial Cancer Study
-
Biogen and Eisai release new Alzheimer's drug data that may support wider uptake
-
Merck and Eisai say two lung-cancer trials failed to meet their main goals
-
Merck, Eisai: Keytruda/Lenvima Combo Fails in Two Non-Small Cell Lung Cancer Studies
-
Merck and Eisai say late-stage trial of treatment for head and neck cancer did not meet goals
-
Biogen's big Alzheimer's drug win fails to boost the stock as analysts see slow Leqembi rollout
-
FDA approves Alzheimer's treatment Leqembi, clearing the way for Medicare coverage
-
Biogen's stock slides premarket as analysts take mixed view of Alzheimer's disease drug approval
Trading Information
- Previous Close Price
- $50.70
- Day Range
- $52.22–52.22
- 52-Week Range
- $50.65–81.03
- Bid/Ask
- $51.11 / $51.71
- Market Cap
- $14.98 Bil
- Volume/Avg
- 1,000 / 795
Key Statistics
- Price/Earnings (Normalized)
- 41.84
- Price/Sales
- 2.74
- Dividend Yield
- 2.10%
- Dividend Yield (Forward)
- 2.26%
- Total Yield
- 2.10%
Company Profile
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of a pharmaceutical business and other businesses. The pharmaceutical business is categorized by region, including Japan, Americas, China, Asia, and Europe, Middle East, and Africa. Eisai also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived by its Japanese pharmaceutical business, followed by its Americas pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Large Growth
- Total Number of Employees
- 11,076
- Website
- http://www.eisai.co.jp
Valuation
|
Metric
|
ESALF
|
|---|---|
Price/Earnings (Normalized) | 41.84 |
Price/Book Value | 2.60 |
Price/Sales | 2.74 |
Price/Cash Flow | 20.37 |
Price/Earnings
ESALF
Financial Strength
|
Metric
|
ESALF
|
|---|---|
Quick Ratio | 1.54 |
Current Ratio | 2.15 |
Interest Coverage | 25.96 |
Quick Ratio
ESALF
Profitability
|
Metric
|
ESALF
|
|---|---|
Return on Assets (Normalized) | 4.05% |
Return on Equity (Normalized) | 6.33% |
Return on Invested Capital (Normalized) | 4.90% |
Return on Assets
ESALF
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Wqwp | $83.5 Bil | |
MKKGY
| Merck KGaA ADR | Cnnlgmb | $67.6 Bil | |
HLN
| Haleon PLC ADR | Jdcw | $37.5 Bil | |
VTRS
| Viatris Inc | Ssrc | $11.7 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Wyxjg | $11.6 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Xft | $10.5 Bil | |
CTLT
| Catalent Inc | Mxrdbn | $6.8 Bil | |
PRGO
| Perrigo Co PLC | Qxtp | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Brgw | $3.1 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Cdswhxk | $3.0 Bil |